Nyxoah SA NYXH 深 滬
等待開盤 11-05 09:30:00 美东时间
0.8974
+0.027
+3.15%
華盛通- 最 高0.919
- 今 開0.8967
- 成交量 7.33万股
- 最 低 0.8922
- 昨 收 0.87
- 總市值 9139.14万
- 52周最高 5.39
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 0.80
- 委 比 66.67%
- 總股本 1.02亿
- 歷史最高 37.00
- 量 比 1.04
- 振 幅 3.08%
- 歷史最低 0.80
- 每 手 1
- 風險率 1.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NYXH收涨0.99%，成交额8.14万美元
11月3日，NYXH（NYXH）收涨0.99%，报0.88美元，成交额8.14万美元，市值8962.99万美元。 行情数据 • 开盘价：0.88美元 • 最高价...
11-03 08:04
Cantor Fitzgerald Maintains Overweight on Nyxoah, Lowers Price Target to $3
Cantor Fitzgerald analyst Sarah James maintains Nyxoah (NASDAQ:NYXH) with a Overweight and lowers the price target from $6 to $3.
10-27 19:37
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Nyxoah SA, a medical technology company, announced it will release its third quarter 2026 financial results on November 5, 2026. Management will host a conference call at 10:30 pm CET / 4:30 pm ET, with a webcast available on the Investor Relations page or via provided links. The Genio system, Nyxoah’s lead solution for Obstructive Sleep Apnea (OSA), received FDA approval in August 2025.
10-26 21:05
NYXH收涨1.51%，成交额15.1万美元
10月24日，NYXH（NYXH）收涨1.51%，报0.83美元，成交额15.1万美元，市值8497.58万美元。 行情数据 • 开盘价：0.86美元 • 最高...
10-24 07:10
NYXH收跌6.72%，成交额23.8万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:03
Nyxoah names new CEO
Nyxoah (NYXH) appointed Liam Kelly as chief executive officer, effective October 1, 2026, succeeding Olivier Taelman. The leadership change comes as Nyxoah transitions toward a U.S.-focused commercial...
09-29 04:49
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah appoints Liam Kelly as Chief Executive Officer, effective October 1, 2026, to strengthen its U.S. presence following FDA approval and the launch of Genio. Kelly brings over 25 years of leadership experience, previously serving as CEO and Chairman of Teleflex Incorporated. Nyxoah focuses on developing innovative solutions for Obstructive Sleep Apnea (OSA), with Genio as its lead product. The appointment underscores the company's strategic s...
09-28 20:30
Nyxoah names Loïc Moreau as interim CFO
Nyxoah (NYXH) said on Monday it appointed President International and former CFO Loïc Moreau as interim CFO, succeeding John Landry, effective Oct. 2, 2026. Moreau brings more than 20 years of finance...
09-22 04:16
Nyxoah Appoints Loic Moreau As Interim CFO, Effective Oct. 2, Succeeding John Landry; Reiterates FY26 Revenue Range Of €36M - €40M
Nyxoah SA (Euronext Brussels/NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role eff...
09-22 04:02
CVRx Appoints John Landry as Chief Financial Officer
CVRx appoints John Landry as Chief Financial Officer, succeeding Jared Oasheim. Landry, with over two decades of experience in medical device finance, joins from Nyxoah SA and previously led Vapotherm's IPO. He will support CVRx's growth, particularly in scaling Barostim, its FDA-approved neuromodulation therapy for heart failure patients. Oasheim is thanked for his contributions since 2015, including leading the company's IPO.
09-21 20:07
